Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Eur J Haematol. 2020 Mar;104(3):190-197. doi: 10.1111/ejh.13358. Epub 2019 Dec 20.
Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging.
While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients.
We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients.
These results support the concept of tumor-specific cell-free DNA as a prognostic marker.
多发性骨髓瘤治疗的进展使患者能够达到更深层次的缓解，因此微小残留病（MRD）的评估至关重要。通常，骨髓样本用于此目的；然而，这种方法受到部位限制。液体活检代表一种微创且更全面的技术，不受部位限制，但同样具有挑战性。
虽然大多数现有数据来自短期研究，但我们提出了一项使用基于 ASO-qPCR 的肿瘤特异性游离 DNA 检测的基于血液的 MRD 监测的长期研究。112 名患者入组该研究，但只有 45 名患者能够进行长期采样和分析。
我们发现肿瘤特异性游离 DNA 水平的数量与具有临床意义的事件显著相关[诱导治疗（P =.004）；ASCT（P =.012）]。此外，cfDNA 片段的长度与患者更好的治疗反应相关。
这些结果支持肿瘤特异性游离 DNA 作为预后标志物的概念。
